Citations

Clear

626 citation(s) found for "Mehta, SH".

Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT
Holtan, Shernan G. , Wang, Tao , Hemmer, Michael, Arora, Mukta , Couriel, Daniel R. , Pidala, Joseph, Abdel‐Azim, Hisham , Ahmed, Ibrahim , Al‐Homsi, A. Samer, Aljurf, Mahmoud , Antin, Joseph H. , Askar, Medhat , Auletta, Jeffery J. , Daly, Andrew , DeFilipp, Zachariah , Gajewski, James , Hematti, Peiman , Hildebrandt, Gerhard , Inamoto, Yoshihiro , Martino, Rodrigo , Majhail, Navneet S. , Marks, David I. , Pawarode, Attaphol , Prestidge, Tim , Rangarajan, Hemalatha G. , Ringdén, Olle , Saad, Ayman , Schoemans, Hélène , Seo, Sachiko , Solh, Melhem , Spitzer, Thomas R. , Storek, Jan , Verdonck, Leo F. , Wirk, Baldeep , Cahn, Jean‐Yves , Weisdorf, Daniel J. , Saad, Ayman , Ringden, Olov , Weisdorf, Dan , Majhail, Navneet S , Martino, Rodrigo , Holtan, Shernan , Auletta, Jeffery J , Hematti, Peiman , Mehta, Rohtesh S. , Spellman, Stephen R. , Alousi, Amin Majid , Agrawal, Vaibhav , Bhatt, Vijaya Raj , Chee, Lynette Chui Yen , Chhabra, Saurabh , Gale, Robert Peter , Gergis, Usama , Hogan, William J. , Nishihori, Taiga , Olsson, Richard F. , Díaz, Miguel Ángel , Savani, Bipin N. , Schultz, Kirk R. , Teshima, Takanori , Yared, Jean A.

Mayo Clinic

Journal of Clinical Oncology | May 4, 2020 | Volume: 38 | Issue: 18 | Pages: 2062-2076

10.1200/jco.19.00396 | PMID 32364845 Get It

PURPOSE There is no consensus on the best choice of an alternative donor (umbilical cord blood [UCB], haploidentical, one-antigen mismatched [7/8]–bone marrow [BM], or 7/8-peripheral blood [PB]) for hematopoietic cell transplantation (HCT) for patients lacking an HLA-matched related or unrelated donor. METHODS We report composite end points of graft-versus-host disease (GVHD)–free relapse-free survival (GRFS) and chronic GVHD (cGVHD)–free relapse-free survival (CRFS) in 2,198 patients who underwent UCB (n = 838), haploidentical (n = 159), 7/8-BM (n = 241), or 7/8-PB (n = 960) HCT. All groups were divided by myeloablative conditioning (MAC) intensity or reduced intensity conditioning (RIC), except haploidentical group in which most received RIC. To account for multiple testing, P < .0071 in multivariable analysis and P < .00025 in direct pairwise comparisons were considered statistically significant. RESULTS In multivariable analysis, haploidentical group had the best GRFS, CRFS, and overall survival (OS). In the direct pairwise comparison of other groups, among those who received MAC, there was no difference in GRFS or CRFS among UCB, 7/8-BM, and 7/8-PB with serotherapy (alemtuzumab or antithymocyte globulin) groups. In contrast, the 7/8-PB without serotherapy group had significantly inferior GRFS, higher cGVHD, and a trend toward worse CRFS (hazard ratio [HR], 1.38; 95% CI, 1.13 to 1.69; P = .002) than the 7/8-BM group and higher cGVHD and trend toward inferior CRFS (HR, 1.36; 95% CI, 1.14 to 1.63; P = .0006) than the UCB group. Among patients with RIC, all groups had significantly inferior GRFS and CRFS compared with the haploidentical group. CONCLUSION Recognizing the limitations of a registry retrospective analysis and the possibility of center selection bias in choosing donors, our data support the use of UCB, 7/8-BM, or 7/8-PB (with serotherapy) grafts for patients undergoing MAC HCT and haploidentical grafts for patients undergoing RIC HCT. The haploidentical group had the best GRFS, CRFS, and OS of all groups.
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
Wen, Patrick Y. , Weller, Michael , Lee, Eudocia Q. , Barnholtz‐Sloan, Jill S. , Barthel, Floris P , Batchelor, Tracy T. , Chang, Susan M. , DeGroot, John, Hegi, Monika E. , Huang, Raymond Y. , Lassman, Andrew B. , Lim, Michael , Mellinghoff, Ingo K. , Minniti, Giuseppe , Nathanson, David A. , Platten, Michael , Preusser, Matthias , Roth, Patrick , Sanson, Marc , Schiff, David , Short, Susan , Taphoorn, Martin , Tonn, Joerg-Christian, Tsang, Jonathan , Verhaak, Roel G.W. , Deimling, Andreas von , Zadeh, Gelareh , Reardon, David A. , Aldape, Kenneth , Bent, Martin J. van den , Weller, Michael , Short, Susan C , van den Bent, Martin J , Barnholtz-Sloan, Jill S , Platten, Michael , Preusser, Matthias , Sanson, Marc , von Deimling, Andreas , Mellinghoff, Ingo K , Huang, Raymond , Roth, Patrick , Barthel, Floris P , Wen, Patrick Yung , Alexander, Brian M. , Bindra, Ranjit S. , Chiocca, E Antonio , Cloughesy, Timothy F. , Galanis, Evanthia , Gilbert, Mark R. , Horbinski, Craig , Rhun, Émilie Le , Mehta, Minesh P. , Tonn, Joerg-Christian , Wick, Wolfgang

Mayo Clinic

Neuro-Oncology | April 20, 2020 | Volume: 22 | Issue: 8 | Pages: 1073-1113

10.1093/neuonc/noaa106 | PMID 32328653 Get It

Abstract Glioblastomas are the most common form of malignant primary brain tumor and an important cause of morbidity and mortality. In recent years there have been important advances in understanding the molecular pathogenesis and biology of these tumors, but this has not translated into significantly improved outcomes for patients. In this consensus review from the Society for Neuro-Oncology (SNO) and the European Association of Neuro-Oncology (EANO), the current management of isocitrate dehydrogenase wildtype (IDHwt) glioblastomas will be discussed. In addition, novel therapies such as targeted molecular therapies, agents targeting DNA damage response and metabolism, immunotherapies, and viral therapies will be reviewed, as well as the current challenges and future directions for research.
90Y Ibritumomab Tiuxetan (Zevalin®; 90YZ) Doses Higher Than .4 mCi/kg May Be Safely Combined with High-Dose Beam and Autotransplant: The Role for Dosimetry.
Inwards, David J. , Spies, Stewart, Wiseman, Gregory A., Erwin, William D. , Rademaker, Alfred , Williams, Stephanie , Tallman, Martin S. , Micallef, Ivana N. , Mehta, Jayesh, Zimmer, Michael, Molina, Arturo , Winter, Jane N. , Patton, David R. , Singhal, Seema , Zimmer, Michael, White, Christine, Gordon, Leo I.

Mayo Clinic

Blood | April 18, 2020 | Volume: 104 | Issue: 11 | Pages: 1162-1162

10.1182/blood.v104.11.1162.1162 Get It

Abstract Twenty-eight patients with relapsed or refractory CD20+ NHL have been enrolled in an ongoing phase I trial of dose-escalated 90YZ followed by high-dose BEAM and autotransplant in which the 90YZ dose is patient-specific based on dosimetry. 90YZ doses are calculated to deliver cohort-defined radiation doses (100, 300, 500, ... cGy) to critical organs (liver, lung or kidney), with 3–6 patients per group. On D -22, rituximab (R) 250 mg/m2 is infused followed by the imaging dose of 111In Zevalin® (5 mCi). Imaging is performed immediately post-injection and at 4, 24, 72, and 144 hours; dosimetry is performed on D -15. On D -14, R 250 mg/m2 is administered followed immediately by 90YZ at the dose calculated to deliver the cohort-prescribed absorbed radiation dose to the critical organ. On D -6 through -1, patients receive high-dose BEAM. On D0, a minimum of 2.0 X 106 CD34+ cells/kg is infused and G-CSF 5 μg/kg SQ daily begun. The median age was 54 (range: 25–72) years. NHL histologic subtypes were as follows: mantle cell 5, diffuse aggressive 13, low grade 5, and transformed 5. Most had received 3 or more treatment regimens, including R. The toxicity profile was similar to that associated with high-dose BEAM and included a decrease in DLCO for most patients with one patient at the 500 cGy dose level experiencing a transient decline to below 50% of the predicted value corrected for hemoglobin. The most common grade III/IV toxicities were infection, fever, stomatitis, nausea, vomiting, diarrhea, hemorrhage, and edema. One patient experienced transient veno-occlusive disease at the 700 cGy dose level. Engraftment occurred at a median of 10 days (range:8–18) to granulocytes ≥ 500/μL, and 21 days (range:13–40days) to platelets ≥20,000/μL . With a median follow-up of one year, the 3 year overall and progression-free survivals are 60% and 50%, respectively. Figure Figure 90-Y Zevalin Dosing by Cohort (median; range) Cohort (cGy) Total Dose (mCi) mCi/kg 100 (n=3) 5 (2–14) .06(.05–.12) 300 (n=7) 22(14–57) .25(.18–.63) 500 (n=6) 31(16–48) .40(.14–.63) 700 (n=6) 37(26–55) .38(.27–.73) 900 (n=3) 28(27–37) .32(.27–.44) 1100 (n=3) 48(29–65) .57(.50–.75) The liver was the critical organ in nearly all cases. Patient-specific doses calculated to deliver a cohort-prescribed absorbed radiation dose to the critical organ were highly variable suggesting that dosing based on weight and not dosimetry is likely to result in a wide range of absorbed dose to critical organs. In the context of this study, 90YZ has been administered to eight patients at doses of .5 mCi/kg or greater. We conclude that with careful dosimetry, 90YZ doses higher than the conventional .4 mCi/kg may be safely combined with BEAM and autotransplant. Accrual continues at the 1300 cGy dose level.
Delayed periorbital hemorrhage in oculoplastic surgery patients on oral anticoagulants
Wagner, Lilly H. , Giese, Isaiah, Mehta, Viraj J. , Seiff, Stuart R., Bradley, Elizabeth A.

Mayo Clinic

Orbit | April 16, 2020 | Volume: 40 | Issue: 2 | Pages: 150-154

10.1080/01676830.2020.1752744 | PMID 32295502 Get It

Mitigating the impact of conference and travel cancellations on researchers’ futures
Weissgerber, Tracey L. , Bediako, Yaw , Winde, Charlotte M. de , Ebrahimi, Hedyeh , Fernández-Chiappe, Florencia , Ilangovan, Vinodh , Mehta, Devang , Quezada, Carolina Paz , Riley, Julia , Saladi, Shyam M. , Tay, Andy , Weissgerber, Tracey L , de Winde, Charlotte M , Paz Quezada, Carolina , Riley, Julia L , Sarabipour, Sarvenaz , Tay, Andy , Ebrahimi, Hedyeh

Mayo Clinic

eLife | March 27, 2020 | Volume: 9 | Issue: No issue available | Pages: No page available

10.7554/elife.57032 | PMID 32216872 Get It

The need to protect public health during the current COVID-19 pandemic has necessitated conference cancellations on an unprecedented scale. As the scientific community adapts to new working conditions, it is important to recognize that some of our actions may disproportionately affect early-career researchers and scientists from countries with limited research funding. We encourage all conference organizers, funders and institutions who are able to do so to consider how they can mitigate the unintended consequences of conference and travel cancellations and we provide seven recommendations for how this could be achieved. The proposed solutions may also offer long-term benefits for those who normally cannot attend conferences, and thus lead to a more equitable future for generations of researchers.
Is caffeine or coffee consumption a risk for new-onset atrial fibrillation? A systematic review and meta-analysis
Krittanawong, Chayakrit , Tunhasiriwet, Anusith, Chirapongsathorn, Sakkarin , Zhang, HongJu, Mehta, Davendra, Farrell, Ann M, Wang, Zhen , Farrell, Ann , Kitai, Takeshi

Mayo Clinic

European Journal of Preventive Cardiology | March 18, 2020 | Volume: 28 | Issue: 12 | Pages: e13-e15

10.1177/2047487320908385 | PMID 34647581 Get It

Molecular predictors of outcome and response to bevacizumab (BEV) based on analysis of RTOG 0825, a phase III trial comparing chemoradiation (CRT) with and without BEV in patients with newly diagnosed glioblastoma (GBM).
Won, Minhee , Blumenthal, Deborah T. , Vogelbaum, Michael A. , Colman, Howard , Jenkins, Robert B. , Brown, Paul D. , Jaeckle, Kurt A. , Schiff, David , Dignam, James J., Atkins, James N., Brachman, David, Werner‐Wasik, Maria, Komaki, Ritsuko , Aldape, Kenneth , Sulman, Erik P. , Colman, Howard , Chakravarti, Arnab , Jeraj, Robert , Gilbert, Mark R. , Mehta, Minesh P.

Mayo Clinic

Journal of Clinical Oncology | March 11, 2020 | Volume: 31 | Issue: 15_suppl | Pages: LBA2010-LBA2010

10.1200/jco.2013.31.15_suppl.lba2010 Get It

LBA2010 The full, final text of this abstract will be available at abstract.asco.org at 7:30 AM (EDT) on Sunday, June, 2, 2013, and in the Annual Meeting Proceedings online supplement to the June 20, 2013, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Sunday edition of ASCO Daily News.
RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM).
Dignam, James J., Won, Minhee , Blumenthal, Deborah T. , Vogelbaum, Michael A. , Aldape, Kenneth , Colman, Howard , Brown, Paul D. , Jaeckle, Kurt A. , Schiff, David , Atkins, James N., Brachman, David, Werner‐Wasik, Maria, Komaki, Ritsuko , Gilbert, Mark R. , Colman, Howard , Chakravarti, Arnab , Jeraj, Robert , Armstrong, Terri S. , Wefel, Jeffrey S. , Sulman, Erik P. , Mehta, Minesh P.

Mayo Clinic

Journal of Clinical Oncology | March 11, 2020 | Volume: 31 | Issue: 15_suppl | Pages: 1-1

10.1200/jco.2013.31.15_suppl.1 Get It

1 The full, final text of this abstract will be available at abstract.asco.org at 7:30 AM (EDT) on Sunday, June, 2, 2013, and in the Annual Meeting Proceedings online supplement to the June 20, 2013, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Sunday edition of ASCO Daily News.
Connect MM: The multiple myeloma (MM) disease registry—Incidence of second primary malignancies (SPM).
Rifkin, Robert M. , Abonour, Rafat , Gasparetto, Cristina , Mehta, Jayesh, Narang, Mohit , Thomas, Sachdev , Shah, Jatin J., Terebelo, Howard R. , Toomey, Kathleen, Minton, Neil, Srinivasan, Shankar , Street, Thomas K., Sullivan, Kristen , Durie, Brian G.M. , Fonseca, Rafaël , Pashos, Chris Leo

Mayo Clinic

Journal of Clinical Oncology | March 11, 2020 | Volume: 30 | Issue: 15_suppl | Pages: 8037-8037

10.1200/jco.2012.30.15_suppl.8037 Get It

8037 Background: Advances in the treatment of MM have greatly improved clinical outcomes for patients (pts). SPM occurrence has been observed in early and late stage MM as well as with increasing age. US SEER Cancer Registry reports a background incidence rate of SPM 2.1/100 person-yrs (PY) among persons ≥ 65 yrs of age. However, incidence of SPM in MM pts and the relationship to therapy still warrants further exploration. Methods: Connect MM is a US-based observational registry designed to characterize pts with newly diagnosed MM from 266 US sites. Initiated in Sep 2009, patient data were collected at baseline and each subsequent quarter with a standardized form. On Dec 14, 2011, Connect MM reached full enrollment at 1,500 pts. Results: As of Jan 13, 2012, preliminary retrospective SPM data is available for 1015 pts. Median age was 67 yrs, 56.8% male, and median follow-up was 10.6 mo (0.03-24.9 mo). 12 pts (7 male) with median age of 68.5 yrs developed SPM. Median time to SPM was 8.5 mo (0.8-17.7 mo) after treatment initiation. 11 invasive SPM were observed - 4 hematological (heme): 1 AML, 1 MDS, 1 CMML and 1 DLBCL, and 7 solid: 2 melanoma skin, 1 bronchus, 1 breast, 1 prostate, 1 tonsil, and 1 gastric carcinoid. Also, 1 pt had non-melanoma skin cancer (NMSC), and 1 pt with invasive skin cancer also had NMSC. Of the 4 pts developing heme SPM, 3 had bortezomib (BORT), 1 had thalidomide (THAL), 1 had lenalidomide (LEN), 2 had melphalan (MEL), and all 4 pts had steroids. Of the 7 pts who developed solid tumor SPM, 5 had BORT, 5 had LEN, 2 had doxorubicin, 1 had MEL, 5 had steroids, 1 had irradiation, and 1 had not received MM treatment. 2 pts with prior history of invasive malignancy developed solid tumor SPM (1 pt also developed NMSC).1 pt who received irradiation developed NMSC. Early overall incidence of invasive SPM was 1.21/100 PY (95% CI 0.60, 2.16) for all pts and 1.20/100 PY (95% CI 0.44,2.62) for pts ≥ 65 yrs of age. Conclusions: This preliminary analysis shows that SPM occurred at an expected rate in this disease specific registry of patients with NDMM and appeared to occur irrespective of MM treatment administered. Incidence rates of SPM may increase over time as patients receive transplantation and alkylators. Prospective observation will continue.
Race- and health-related quality of life among patients newly diagnosed with multiple myeloma.
Durie, Brian G.M. , Rifkin, Robert M. , Abonour, Rafat , Gasparetto, Cristina, Mehta, Jayesh, Narang, Mohit , Shah, Jatin J., Terebelo, Howard R. , Thomas, Sachdev , Toomey, Kathleen, Swern, Arlene S., Harding, Gale, Sullivan, Kristen , Street, Thomas K., Khan, Zeba M., Pashos, Chris Leo , Fonseca, Rafaël , Gasparetto, Cristina

Mayo Clinic

Journal of Clinical Oncology | March 11, 2020 | Volume: 30 | Issue: 15_suppl | Pages: e18556-e18556

10.1200/jco.2012.30.15_suppl.e18556 Get It

e18556 Background: Studies in the United States (US) have identified variation in incidence and survival of multiple myeloma (MM) patients of different races, and noted that MM is the most common hematologic cancer among African Americans. This analysis evaluated whether health-related quality of life (HRQOL) of patients in the US varies by race as they initiate treatment having been newly diagnosed with active, symptomatic MM. Methods: Data were collected in Connect MM, a prospective US observational registry begun in September 2009. Data on patient demographics and clinical characteristics were provided by clinicians. HRQOL was reported by patients at enrollment within 2 months of diagnosis. Patients completed the Brief Pain Inventory (BPI), EQ-5D, and Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM). Mean reported scores for BPI, EQ-5D and FACT-MM were analyzed by patient race. Statistical significance was ascertained by ANOVA using SAS 9.1. Results: Baseline HRQOL data were reported by 1144 patients (enrolled in 228 centers) of whom 82% were White, 13% Black, and 6% Other race. The cohorts did not differ statistically by ECOG status or by multiple myeloma stage (assessed by either the International Staging System or the Durie and Salmon system). Compared to non-Blacks, Black patients reported less anxiety/depression on the EQ-5D (p=0.030) and better emotional well-being on the FACT-MM (p=0.003). No other statistically significant differences were noted between cohorts on the BPI, other EQ-5D domains (mobility, self care, usual activities, pain/discomfort), or other FACT-MM domains (physical, social/family, functional, and MM-specific considerations). Conclusions: Initial results from the Connect MM Registry indicate that baseline HRQOL prior to initiation of treatment may vary by patient race with respect to emotional well-being, and specifically anxiety/depression. These results serve as a baseline reference for future analyses. As patients in the Connect MM Registry proceed through therapy, analyses should be conducted of patients by race, among other characteristics and factors, to determine whether it may be associated with subsequent clinical outcomes and HRQOL over time.